Elicio Therapeutics (ELTX) Stock Statistics & Valuation Metrics

Elicio Therapeutics has a market cap or net worth of $149.50M. The enterprise value is $116.79M.

Elicio Therapeutics has 16,338,284 shares outstanding. The number of shares has decreased by -2.65% in one year.

Elicio Therapeutics’s return on equity (ROE) is 4.59 and return on invested capital (ROIC) is -256.24%.

The current PE Ratio of Elicio Therapeutics is ―. Elicio Therapeutics’s PEG ratio is 0.03.

In the last 12 months, Elicio Therapeutics had revenue of 0.00 and earned -51.90M in profits. Earnings per share was -4.25.

In the last 12 months, operating cash flow was -38.90M and capital expenditures -45.00K, giving a free cash flow of -38.94M billion.

Elicio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Elicio Therapeutics upcoming earnings date is Mar 27, 2026, After Close (Confirmed).

Elicio Therapeutics as a current ratio of 1.80, with Debt / Equity ratio of 139.86%

In the past 12 months, Elicio Therapeutics has paid 0.00 in taxes.

Elicio Therapeutics EV to EBITDA ratio is -1.41, with an EV/FCF ratio of -1.90.

Elicio Therapeutics has $20.61M in cash and marketable securities with $5.34M in debt, giving a net cash position of $15.27M billion.

Gross margin is 2.06%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Elicio Therapeutics is $15.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy